CN1507885A - Medicinal formula of calculus bovis cold-clearing capsule - Google Patents
Medicinal formula of calculus bovis cold-clearing capsule Download PDFInfo
- Publication number
- CN1507885A CN1507885A CNA021449260A CN02144926A CN1507885A CN 1507885 A CN1507885 A CN 1507885A CN A021449260 A CNA021449260 A CN A021449260A CN 02144926 A CN02144926 A CN 02144926A CN 1507885 A CN1507885 A CN 1507885A
- Authority
- CN
- China
- Prior art keywords
- calculus bovis
- radix scutellariae
- fructus forsythiae
- flos lonicerae
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a prescription of neuhuang qinggan capsule with the functions of resisting bacteria, resisting virus and relieving fever for curing common cold with high obvious therapeutic effect. Said prescription contains several Chinese medicinal materials of artificial bovine bezoar, lonicera flower, scutellaria root, forsythia fruit, abalone shell powder and others.
Description
Affiliated technical field
The present invention relates to a kind of prescription of Chinese medicine, particularly relate to a kind of prescription of Calculus Bovis Qinggan capsules.
Background technology
At present, the pharmacopoeia class of the relevant treatment flu of China's Chinese medicine is more, and it is formulated by Chinese medicines such as Flos Lonicerae, Radix Scutellariae, Fructus Forsythiaes as SHUANGHUANLIAN Chinese medicine, and this Chinese medicine has effects such as anti-bacteria and anti-virus, but do not have analgesic function, need share with other medicines could treatment flu effectively comprehensively.
Summary of the invention
The object of the present invention is to provide a kind of prescription rationally to have antibiotic, antiviral, the analgesic effect of bringing down a fever, the prescription of the Calculus Bovis Qinggan capsules Chinese medicine of treatment flu.
In order to achieve the above object, the technical solution used in the present invention is:
Artificial Calculus Bovis 5.6-11.3%
Flos Lonicerae 18.9%
Radix Scutellariae 18.9-28.3%
Fructus Forsythiae 37.7%
Concha Margaritifera powder 9.4-18.9%
Advantage of the present invention is
Prescription is reasonable, no side effects, and it has brought into play the advantage of SHUANGHUANLIAN Chinese medicine preparation, brings down a fever, resists frightened effect better than SHUANGHUANLIAN Chinese medicine is analgesic, the effect with various symptoms of analgesic, comprehensive treatment flu.
The specific embodiment
Below embodiments of the invention are described in further detail
Embodiment 1
Artificial Calculus Bovis 5.6g Flos Lonicerae 18.9g Radix Scutellariae 18.9g Fructus Forsythiae 37.7g Concha Margaritifera powder 18.9g
Embodiment 2
Artificial Calculus Bovis 7.5g Flos Lonicerae 18.9g Radix Scutellariae 18.9g Fructus Forsythiae 37.7g Concha Margaritifera powder 17.0g
Embodiment 3
Artificial Calculus Bovis 9.4g Flos Lonicerae 18.9g Radix Scutellariae 18.9g Fructus Forsythiae 37.7g Concha Margaritifera powder 15.1g
Embodiment 4
Artificial Calculus Bovis 11.3g Flos Lonicerae 18.9g Radix Scutellariae 18.9g Fructus Forsythiae 37.7g Concha Margaritifera powder 13.2g
Embodiment 5
Artificial Calculus Bovis 5.7g Flos Lonicerae 18.9g Radix Scutellariae 28.3g Fructus Forsythiae 37.7g Concha Margaritifera powder 9.4g
Embodiment 6
Artificial Calculus Bovis 5.7g Flos Lonicerae 18.9g Radix Scutellariae 26.4g Fructus Forsythiae 37.7g Concha Margaritifera powder 11.3g
Embodiment 7
Artificial Calculus Bovis 5.7g Flos Lonicerae 18.9g Radix Scutellariae 24.5g Fructus Forsythiae 37.7g Concha Margaritifera powder 13.2g
Embodiment 8
Artificial Calculus Bovis 5.7g Flos Lonicerae 18.9g Radix Scutellariae 22.6g Fructus Forsythiae 37.7g Concha Margaritifera powder 15.1g
Embodiment 9
Artificial Calculus Bovis 5.7g Flos Lonicerae 18.9g Radix Scutellariae 20.7g Fructus Forsythiae 37.7g Concha Margaritifera powder 17.0g
Embodiment 10
Artificial Calculus Bovis 7.5g Flos Lonicerae 18.9g Radix Scutellariae 20.8g Fructus Forsythiae 37.7g Concha Margaritifera powder 15.1g
Embodiment 11
Artificial Calculus Bovis 7.5g Flos Lonicerae 18.9g Radix Scutellariae 22.7g Fructus Forsythiae 37.7g Concha Margaritifera powder 13.2g
Embodiment 12
Artificial Calculus Bovis 7.5g Flos Lonicerae 18.9g Radix Scutellariae 24.6g Fructus Forsythiae 37.7g Concha Margaritifera powder 11.3g
Embodiment 13
Artificial Calculus Bovis 9.4g Flos Lonicerae 18.9g Radix Scutellariae 20.8g Fructus Forsythiae 37.7g Concha Margaritifera powder 13.2g
Embodiment 14
Artificial Calculus Bovis 9.4g Flos Lonicerae 18.9g Radix Scutellariae 22.7g Fructus Forsythiae 37.7g Concha Margaritifera powder 11.3g
Embodiment 15
Artificial Calculus Bovis 11.3g Flos Lonicerae 18.9g Radix Scutellariae 20.8g Fructus Forsythiae 37.7g Concha Margaritifera powder 11.3g
The present invention advances clinical trial through Heilongjiang Province Affiliated Hospital of university of TCM Respiratory Medicine proves that it has the effect of heat-clearing and toxic substances removing, waking up the patient from unconsciousness by dissipating phlegm, is usually used in treating various respiratory tract infection clinically.For observing the clinical efficacy of Calculus Bovis Qinggan capsules, this institute has used 6 months time to do following observation, now is reported as follows:
1. data and method
1.1 case is selected
The outpatient on March 18th, 1 1998 on the 2nd August in 1997, totally 100 examples, 38.1 years old mean age was two groups with component, each 50 example of treatment group (taking the Calculus Bovis Qinggan capsules) and observation group's (taking SHUANGHUANGLIAN KOUFUYE).Upper respiratory tract infection person's 55 examples wherein, tonsillitis 18 examples, pneumonia 27 examples.Not within selected scope, all case histories all meet the standard of respiratory tract infection for anemia of pregnant woman, women breast-feeding their children and critically ill patient.
1.2 Therapeutic Method
The treatment group is thrown each 3 of Calculus Bovis Qinggan capsules (lot number 970606,970607), and oral every day 3 times, the course of treatment 7 is big.
Matched group throw the SHUANGHUANGLIAN KOUFUYE that Qingan County, Heilongjiang Province pharmaceutical factory produces (lot number: 970516,970517) each 2, oral every day 3 times, curative effect 7 days.Medicines such as inactive all antibiotics of period in a medicine and antipyretic-antalgic.
1.3 observation index
Patient's subjective symptoms: as headache, watery nasal discharge, pharyngalgia, cough etc.; Clinical sign: whether enlargement of tonsil, pulmonary rale and sign; Laboratory checking index is as routine blood test, chest x-ray etc.
1.4 curative effect determinate standard
Cure: subjective symptoms disappears, and sign is normal, and it is normal that lab index is all recovered.
Produce effects: subjective symptoms alleviates, and sign takes a turn for the better to some extent, and the amygdala enlargement reduces, pulmonary rale minimizing etc.;
Effectively: subjective symptoms alleviates to some extent, and sign does not have and is clearly better, and it is normal that lab testing does not recover;
Invalid: subjective symptoms does not have improvement, and sign and lab testing all do not have change.
2. result
Two groups of curative effects relatively see Table 1.
Table 1
Group example number is cured effectively (%) invalid (%) total effective rate (%) of (%) produce effects (%)
Treatment organizes 50 25 (50) 14 (28) 9 (18) 2 (4) 96
Matched group 50 11 (22) 16 (32) 12 (24) 11 (22) 78
Learn by statistics and handle, treatment group cure rate is apparently higher than matched group (X
2=8.51, P＜0.01), treatment group total effective rate is apparently higher than matched group (X
2=7.16, P＜0.01).
3. discuss
The Calculus Bovis Qinggan capsules is a pure Chinese medicinal preparation, is made up of artificial Calculus Bovis, Radix Scutellariae, Fructus Forsythiae etc.Calculus Bovis have clear away heart-fire reduce phlegm, effect that function of gallbladder promoting is relieving convulsion; Radix Scutellariae removing the relative excess fire, except that damp and hot, Fructus Forsythiae heat-clearing and toxic substances removing, mass dissipating and swelling eliminating, three medicines share, and play the effect of its heat clearing away toxin expelling, waking up the patient from unconsciousness by dissipating phlegm altogether.Modern pharmacology has confirmed that Calculus Bovis has the obvious suppression effect to inflammation, remarkable inflammation-inhibiting position N in the antiinflammatory process
2O content helps the absorption of inflammation
[1]Baicalin, Radix Scutellariae unit all guinea pig in vitro foot pawl anaphylaxis are shunk and the whole animal allergic asthma has mitigation, and tangible antiinflammatory, anti-allergy action are arranged
[2]The antibacterial and anti-inflammation functions of Fructus Forsythiae also has confirmation in modern pharmacology
[3]Therefore, the Calculus Bovis Qinggan capsules is a good medicine that is worth exploitation to apply to clinical treatment upper respiratory tract infection.
[1] Li Xia etc., the preliminary discussion of cultivating artificial calculus bovis's antiinflammatory action and inhibition thereof " Shenyang Pharmaceutical University's journal on November 20th, 1996; 17 (6) .431-433.
[2] [3] Chinese herbal medicine dictionary.
Year May in October, 1997 to 1,998 50 routine upper respiratory tract infection patients are carried out clinical observation through No.1 Hospital Attached to Harbin Medical Univ.'s Respiratory Medicine, now the result are reported as follows:
Data and method
One, object
Acute upper respiratory tract infection patient 100 examples all from this institute's Respiratory Medicine outpatient service, are divided into two groups at random, and every group of each 50 example, age and sex distribute and are shown in Table 1:
Table 1 sex and age distribution
Group men and women's age
Treatment organizes 23 27 34.68 ± 16.23
Matched group 22 28 36.42 ± 15.46
P＞0.05
Two, medication
1, treatment group: Calculus Bovis Qinggan capsules (lot number 970415,970416), each 3, every day 3 times, oral.
2, matched group: cow-bezoar antiphlogistic tablet (Shiyitang Pharmaceutic Plant, lot number: 970112,970113), each 3, every day 3 times, oral.
Three, observation item
1, symptom: pharyngalgia, watery nasal discharge, nasal obstruction, beat spray, the headache.
2, sign: body temperature, pharyngeal hyperemia, antiadoncus.
3, chemical examination: routine blood test, routine urinalysis.
Four, curative effect judging standard
By recover, produce effects, progress, invalid four groups of evaluations.
Recover: symptom, sign, lab testing all recover normal.
Produce effects: the state of an illness take a favorable turn, but has one not recover normal fully in above-mentioned three.
Progressive: the state of an illness take a favorable turn after the medication, but obvious inadequately.
Invalid: medication after 72 hours the state of an illness do not have and be clearly better or the person of increasing the weight of.
Recovery from illness adds up to produce effects and is called effectively, and calculates effective percentage.
Table 2 liang group patient clinical manifestation
Group watery nasal discharge fever and headache pharyngalgia pharyngeal hyperemia tonsil is played spray greatly
Treatment organizes 22 36 16 32 38 16 12
Matched group 20 39 14 30 35 17 11
Table 3 liang group lab index
Total white blood cells neutrophilic granulocyte (%) group
＜0.4 * 10
9/ L≤10 * 10
9/ L＞10 * 10
94 24 22 36 14 matched groups 5 22 23 38 12 are organized in/L≤70＞70 treatments
The result
The contrast of table 4 MAIN OUTCOME MEASURES
The disappearance of jet flow tears is played on average bring down a fever pharyngeal hyperemia disappearance tonsil detumescence of group
Treatment group 3.46 ± 1.46 4.76 ± 1.62 4.82 ± 1.53 2.63 ± 1.25
Matched group 3.42 ± 1.56 5.02 ± 1.49 4.96 ± 1.62 2.78 ± 1.46
P all＞0.05
Table 5 clinical efficacy
The invalid effective percentage of group example number recovery from illness produce effects progress
Treatment organizes 50 32 10 44 84%
Matched group 50 28 886 72%
P＞0.05
Two groups there is no obvious toxic-side effects, treatment front and back routine urinalysis all in normal range.
Claims (1)
1, a kind of prescription of Calculus Bovis Qinggan capsules is characterized in that:
Below each compositions in weight percentage
Artificial Calculus Bovis 5.6-11.3%
Flos Lonicerae 18.9%
Radix Scutellariae 18.9-28.3%
Fructus Forsythiae 37.7%
Concha Margaritifera powder 9.4-18.9%
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021449260A CN1283277C (en) | 2002-12-13 | 2002-12-13 | Medicinal formula of calculus bovis cold-clearing capsule |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021449260A CN1283277C (en) | 2002-12-13 | 2002-12-13 | Medicinal formula of calculus bovis cold-clearing capsule |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1507885A true CN1507885A (en) | 2004-06-30 |
| CN1283277C CN1283277C (en) | 2006-11-08 |
Family
ID=34232166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021449260A Expired - Lifetime CN1283277C (en) | 2002-12-13 | 2002-12-13 | Medicinal formula of calculus bovis cold-clearing capsule |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1283277C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103230441A (en) * | 2013-04-08 | 2013-08-07 | 周有财 | Medicine composition, preparation thereof, and application thereof |
| CN103690509A (en) * | 2013-11-27 | 2014-04-02 | 周有财 | Bezoar cold-clearing capsule and preparation method thereof |
| CN104547304A (en) * | 2015-02-09 | 2015-04-29 | 柏伟伟 | Traditional Chinese medicine formula and preparation method of periodontal blood-activating powder |
-
2002
- 2002-12-13 CN CNB021449260A patent/CN1283277C/en not_active Expired - Lifetime
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103230441A (en) * | 2013-04-08 | 2013-08-07 | 周有财 | Medicine composition, preparation thereof, and application thereof |
| CN103690509A (en) * | 2013-11-27 | 2014-04-02 | 周有财 | Bezoar cold-clearing capsule and preparation method thereof |
| CN104547304A (en) * | 2015-02-09 | 2015-04-29 | 柏伟伟 | Traditional Chinese medicine formula and preparation method of periodontal blood-activating powder |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1283277C (en) | 2006-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1768812A (en) | Medicinal composition for removing dampness to relieve itching and its preparation method and uses | |
| CN1836720A (en) | Chinese medicine composition for treating arthritis or gout and preparing method thereof | |
| CN1861163A (en) | Traditional Chinese medicine composition for treating kidney-yang deficiency and deficiency of vital energy and blood, its prepn. process | |
| CN1210047C (en) | Medicine for treating common cold and preparation method | |
| CN1056775C (en) | Drug for curing stone of urinary system | |
| CN1899530A (en) | Medicine for preventing and controlling chicken infectious laryngotracheitis | |
| CN1283277C (en) | Medicinal formula of calculus bovis cold-clearing capsule | |
| CN1973878A (en) | Medicine for treating children's stomachache and its prepn | |
| CN1634479A (en) | Medicine composition for treating cold and upper respiratory tract infection, preparation method and purpose thereof | |
| CN1168488C (en) | Chinese medicinal preparation for treating pyretic stranguria | |
| CN1229129C (en) | Adhibition ointment for relieving cough | |
| CN100337644C (en) | Chinese medicine for treating peptic ulcer and its prepn process | |
| CN1186067C (en) | Medicine for curing acute injury of muscle and tendon and its preparation method | |
| CN1443545A (en) | Medicine for curing acne and its preparation method | |
| CN1161132C (en) | Tibetan medicine for treating hepatism and its preparing process | |
| CN1350868A (en) | Medicine for preventing and treating cold and its preparing process | |
| CN1799603A (en) | Chinese traditional medicine composition for treating rheumatic or rheumatoid disease and preparation method thereof | |
| CN1772098A (en) | Chinese medicine composition for treating chronic pharyngitis and phlegm-heat and its prepn process | |
| CN1248709C (en) | Chinese medicine prepn for stopping drug addiction | |
| CN101028470A (en) | Medicinal composition for treating phthisis | |
| CN1475261A (en) | Medicine for treating gastral cavity pain and its preparation method | |
| CN1286519C (en) | Medicinal composition for treating cholelithiasis and its preparing method | |
| CN100346816C (en) | Chinese medicine composition for preventing and treating influenza | |
| CN1628770A (en) | Cough stopping and asthma relieving medicine and its preparation | |
| CN1189208C (en) | Chinese medicine composition for curing child common cold fever |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: HEILONGJIANG AOLIDA NAIDE PHARMACEUTICAL Co.,Ltd. Assignor: Zhou Youcai Contract record no.: 2011230000208 Denomination of invention: Medicine composition for treating common cold and its preparing method Granted publication date: 20061108 License type: Exclusive License Open date: 20040630 Record date: 20110822 |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20191223 Address after: 152400 No. 18 Economic Development Zone, Qing'an County, Heilongjiang, Suihua Patentee after: HEILONGJIANG AOLIDA NAIDE PHARMACEUTICAL Co.,Ltd. Address before: Nangang District of Heilongjiang city in Harbin Province, 150001 east straight Street No. 259 building 25 layer industry Patentee before: Zhou Youcai |
|
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20061108 |